Singapur - anglès - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - pegfilgrastim - injection, solution - 6mg - pegfilgrastim 6mg/0.6ml

Unió Europea - anglès - EMA (European Medicines Agency)

dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Israel - anglès - Ministry of Health

amgen europe b.v. - pegfilgrastim - solution for injection - pegfilgrastim 10 mg/ml ml - pegfilgrastim - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. ( with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Singapur - anglès - HSA (Health Sciences Authority)

kyowa hakko kirin (singapore) pte. ltd. - pegfilgrastim - injection, solution, concentrate - 6mg/0.6 ml

Unió Europea - anglès - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - neutropenia; cancer - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Unió Europea - anglès - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - pegfilgrastim - solution for injection - 10mg/1ml

Unió Europea - anglès - EMA (European Medicines Agency)

accord healthcare s.l.u. - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Unió Europea - anglès - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Unió Europea - anglès - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenia - immunostimulants, - to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy.